Melbourne-based Mesoblast (ASX:MSB) has signed a process development and manufacturing agreement with US life sciences company Cambrex Corporation (NYSE:CMB) for the large scale production of Mesoblast's adult stem cells. [ + ]

Perth-based biomedical devices developer Visiomed Group (ASX:VSG) has successfully competed negotiations with three pharmaceutical wholesale distributors in Australia for the distribution of its Funhaler incentive asthma spacer into Australian pharmacies. [ + ]

Melbourne's Phosphagenics (ASX:POH) has successfully delivered insulin through the skin of animals using its patented transdermal drug delivery system TPM-01. [ + ]

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial. [ + ]

Sydney oncology therapy developer Psiron (ASX:PSX) has announced a delay in reporting the results of its first phase I clinical trial of its cancer-slaying CVA 21 viral therapy in melanoma patients because of delays in access to supplies of the virus. [ + ]

Premier Bionics (ASX:PBI) subsidiary Pulmosonix will continue with the development of its PulmoScreen device which measures lung damage following the successful completion of a proof-of-concept trial. [ + ]

Melbourne's Amrad Corporation (ASX:AML) will be seeking approval from shareholders to change its name. [ + ]

Unable to secure sufficient funds with its first attempt at an IPO, Sydney-based Medical Therapies has issued a replacement prospectus which CEO Llewellyn Casbolt believes has "uncluttered and demystified the company and its technologies". [ + ]

Eqitx (ASX:EQX) and PharmAust (ASX:PAA) subsidiary Mimotopes have signed a partnership deal to jointly develop new targets for therapeutic or diagnostic approaches. [ + ]

Melbourne biopharma Cryptome Pharmaceuticals (ASX:CRP) has signed a collaboration agreement with the University of Virginia for the further discovery of compounds to treat 'vascular leak' -- a major component of inflammatory disorders and tissue damage associated with stroke, heart attacks and MS. [ + ]

Antibody developer EvoGenix (ASX:EGX) has signed a licensing deal with Dinona for one of the South Korean biotech's anti-leukaemia antibodies. [ + ]

Brisbane-based Agenix (ASX:AGX, NASDAQ:OTC:AGXLY) has lodged a prospectus for an underwritten non-renounceable rights issue to raise $9.85 million before costs. [ + ]

Melbourne-based CogState (ASX:CGS) has distanced itself from the biotech sector, in a move that CEO Peter Bick described as "bowing to popular pressure that biotechs are highly risky and expensive businesses". [ + ]

La Trobe University is one of a number of Australian and overseas universities and other organisations sharing a $9 million ARC grant over five years to develop a Centre of Excellence in Coherent X-ray Science.

Norwood Devices, a division of medical technologies group Norwood Abbey (ASX:NAL) has received approval from the Russian Ministry of Health to import and sell the Norwood EyeCare Epi-LASIK system. [ + ]